The research article supports the notion that combining ruxolitinib with HER2-targeted agents could inhibit the development of drug resistance in the metastatic setting and prolong patient response to ErbB-targeted agents. #breastcancer @LifeAtPurdue ht…
RT @WendtLab_cancer: New paper out today showing TG2:NF-kB:IL6:STAT3 signaling can bridge the gap between HER2 and bypass mechanisms of dru…
Congrats to all contributors!
RT @WendtLab_cancer: New paper out today showing TG2:NF-kB:IL6:STAT3 signaling can bridge the gap between HER2 and bypass mechanisms of dru…